Acelyrin, Inc. (NASDAQ:SLRN) Shares Purchased by Geode Capital Management LLC

Geode Capital Management LLC grew its holdings in shares of Acelyrin, Inc. (NASDAQ:SLRN) by 30.8% in the third quarter, according to its most recent filing with the SEC. The firm owned 1,651,614 shares of the company’s stock after acquiring an additional 388,631 shares during the quarter. Geode Capital Management LLC owned about 1.65% of Acelyrin worth $8,144,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of SLRN. HighTower Advisors LLC acquired a new position in Acelyrin during the 3rd quarter valued at about $50,000. Principal Financial Group Inc. bought a new position in shares of Acelyrin in the second quarter valued at approximately $49,000. Intech Investment Management LLC acquired a new position in shares of Acelyrin during the third quarter valued at approximately $77,000. US Bancorp DE increased its stake in shares of Acelyrin by 77.1% during the third quarter. US Bancorp DE now owns 16,854 shares of the company’s stock valued at $83,000 after acquiring an additional 7,336 shares during the period. Finally, China Universal Asset Management Co. Ltd. raised its holdings in Acelyrin by 65.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 19,196 shares of the company’s stock worth $95,000 after purchasing an additional 7,560 shares in the last quarter. Institutional investors own 87.31% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on SLRN. HC Wainwright reaffirmed a “neutral” rating and set a $8.00 price target on shares of Acelyrin in a research note on Wednesday, December 11th. Wells Fargo & Company decreased their target price on Acelyrin from $15.00 to $13.00 and set an “overweight” rating for the company in a research note on Wednesday, December 11th.

Acelyrin Stock Performance

Shares of NASDAQ:SLRN opened at $3.30 on Friday. The stock has a market capitalization of $331.08 million, a price-to-earnings ratio of -1.34 and a beta of 1.63. Acelyrin, Inc. has a 1-year low of $3.05 and a 1-year high of $8.89. The company has a 50 day moving average price of $4.49 and a 200 day moving average price of $4.89.

About Acelyrin

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.